Comparison of clinical efficacy and safety of weekly GLP-1 receptor agonists dulaglutide and semaglutide
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000044264
- Lead Sponsor
- Kawasai Medical School
- Brief Summary
The primary endpoint was the difference of HbA1c level between 2 groups at 24 weeks. The HbA1c level at 24 weeks was significantly lower in S than D. Reduction in BMI and VFA levels were also more significant in S, BMI: 29.2 to 28.8 vs. 29.4 to 28.1
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
Type 1 diabetes patient Patients using insulin Patients treated with GLP-1 receptor agonist within 3 months Patients with a history of severe ketosis, diabetic coma, or precoma within the last 6 months Pregnant or potentially pregnant women and lactating patients Diabetic patients with specific mechanisms and diseases (exocrine pancreatic disease, endocrine disease, drug-induced, hereditary) Cases during steroid administration Patients with malignant tumors Patients with severe infections, before and after surgery, and with serious trauma Patients with severe liver damage Other cases judged to be inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of HbA1c levels between the two groups 6 months after the start of administration.
- Secondary Outcome Measures
Name Time Method